Home Blog of Signal Transduction Transmembrane Transporters CFTR

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

CFTR

Discovery of novel 7,8-dihydropteridine-6(5H)-one-based DNA-PK inhibitors as potential anticancer agents via scaffold hopping strategy

28 views | May 13 2022

Zongbao Ding et al. thought that DK1 was a novel DNA-PK inhibitor with great promise for further study. [Read the Full Post]

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine

31 views | May 13 2022

Mairead Kelly et al. showed that dual therapies combining a CFTR corrector with a CFTR potentiator had a comparable correction efficacy for CFTR activity in F508del-homozygous HNE cells. [Read the Full Post]

Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer

34 views | Apr 25 2022

Dimitrios Korentzelos et al. suggested that IFNγ might be useful in combinatorial regimens to induce sensitivity to immunotherapy and chemotherapy in hepatic metastases of mCRPC. [Read the Full Post]

CFTR limits F-actin formation and promotes morphological alignment with flow in human lung microvascular endothelial cells

94 views | Jan 25 2022

Adam J Causer showed that CFTR appeared to limit cytosolic actin polymerization, while maintaining a cortical rim actin distribution that was important for maintaining barrier integrity and promoting alignment with flow, without effects on endothelial nitrite or ET-1 production. [Read the Full Post]

Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators

121 views | Dec 27 2021

Danya Muilwijk et al. thought that the PEx rate prior to CFTR modulator treatment initiation, sex and SwCl at baseline could be potential predictors of long-term PEx rate and of changes in SwCl after modulator initiation. [Read the Full Post]

Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR

218 views | Sep 14 2021

David Drummond et al. suggested a potential beneficial effect of CFTR modulators on CF liver disease and warrant further investigation in larger, prospective studies. [Read the Full Post]

A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants

224 views | Aug 13 2021

Guido Veit et al. thought that HNE, as a precision medicine model, enabled the optimization of mutation-specific modulator combinations to maximize their efficacy and minimize life-long drug exposure of CF patients. [Read the Full Post]

Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control

208 views | Jun 22 2021

Kyoko Nakamura et al. found that blocking the NHEJ DNA repair pathway with AZD7648 in combination with RT leaded to durable immune-mediated tumor control. [Read the Full Post]

Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment

226 views | Jun 21 2021

Valeria Capurro et al. thought that it was still possible to further improve mutant CFTR rescue with the development of corrector combinations having maximal effects on mutant CFTR structural and functional properties. [Read the Full Post]

GDI2 is a target of paclitaxel that affects tumorigenesis of prostate cancer via the p75NTR signaling pathway

204 views | May 31 2021

Chi Liu et al. found that knocking down of GDI2 inhibited cell proliferation and promoted cell apoptosis via the p75NTR signaling pathway in prostate cancer. [Read the Full Post]